Blarcamesine Shows Promise in Reducing Alzheimer’s Biomarkers in Phase 2b/3 Trial
OnA recent study by Anavex Life Sciences has unveiled promising results for their investigational Alzheimer’s agent, blarcamesine. The phase 2b/3 trial, conducted across multiple.
Read More